Financhill
Sell
27

VKTX Quote, Financials, Valuation and Earnings

Last price:
$29.34
Seasonality move :
26.12%
Day range:
$29.08 - $29.99
52-week range:
$29.08 - $99.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.80x
Volume:
4.7M
Avg. volume:
4M
1-year change:
-2.03%
Market cap:
$3.3B
Revenue:
--
EPS (TTM):
-$1.00

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
VKTX
Viking Therapeutics
-- -$0.27 -- -25.22% $99.13
AMGN
Amgen
$8.9B $5.08 8.64% 257.4% $316.70
LLY
Eli Lilly and
$13.4B $5.07 45.96% 90.83% $979.86
MRK
Merck &
$15.5B $1.67 -0.23% 13.87% $116.67
PFE
Pfizer
$17.3B $0.46 -3.36% 28.85% $31.18
VRTX
Vertex Pharmaceuticals
$2.8B $4.02 4.7% 15.92% $498.34
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
VKTX
Viking Therapeutics
$29.96 $99.13 $3.3B -- $0.00 0% --
AMGN
Amgen
$296.66 $316.70 $159.5B 39.29x $2.25 3.03% 4.80x
LLY
Eli Lilly and
$865.00 $979.86 $777.9B 73.87x $1.30 0.6% 17.36x
MRK
Merck &
$86.54 $116.67 $218.9B 12.86x $0.81 3.61% 3.43x
PFE
Pfizer
$25.53 $31.18 $144.7B 18.11x $0.43 6.62% 2.29x
VRTX
Vertex Pharmaceuticals
$455.22 $498.34 $116.9B 26.10x $0.00 0% 10.75x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
VKTX
Viking Therapeutics
-- 5.815 -- --
AMGN
Amgen
91.09% 0.218 42.9% 0.81x
LLY
Eli Lilly and
68.61% 1.194 -- 0.63x
MRK
Merck &
46.15% 0.628 -- 0.88x
PFE
Pfizer
41.92% 0.484 -- 0.64x
VRTX
Vertex Pharmaceuticals
-- 1.257 -- 2.17x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
VKTX
Viking Therapeutics
-- -$46.2M -- -- -- -$22M
AMGN
Amgen
$6B $2.3B 5.97% 66.87% 16.83% $5.5B
LLY
Eli Lilly and
$11.1B $5.7B 25.96% 66.4% 41.99% -$458.9M
MRK
Merck &
$11.8B $4.3B 21.98% 29.26% 27.82% $8.5B
PFE
Pfizer
$11.9B $3.2B 5.04% 4.63% 4.1% $6.1B
VRTX
Vertex Pharmaceuticals
$2.5B $1.1B -3.23% -3.23% 39.12% $1.3B

Viking Therapeutics vs. Competitors

  • Which has Higher Returns VKTX or AMGN?

    Amgen has a net margin of -- compared to Viking Therapeutics's net margin of 6.9%. Viking Therapeutics's return on equity of -- beat Amgen's return on equity of 66.87%.

    Company Gross Margin Earnings Per Share Invested Capital
    VKTX
    Viking Therapeutics
    -- -$0.32 --
    AMGN
    Amgen
    65.75% $1.16 $66B
  • What do Analysts Say About VKTX or AMGN?

    Viking Therapeutics has a consensus price target of $99.13, signalling upside risk potential of 230.86%. On the other hand Amgen has an analysts' consensus of $316.70 which suggests that it could grow by 6.76%. Given that Viking Therapeutics has higher upside potential than Amgen, analysts believe Viking Therapeutics is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    VKTX
    Viking Therapeutics
    9 1 0
    AMGN
    Amgen
    9 15 2
  • Is VKTX or AMGN More Risky?

    Viking Therapeutics has a beta of 0.900, which suggesting that the stock is 10.034% less volatile than S&P 500. In comparison Amgen has a beta of 0.559, suggesting its less volatile than the S&P 500 by 44.064%.

  • Which is a Better Dividend Stock VKTX or AMGN?

    Viking Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 3.03% to investors and pays a quarterly dividend of $2.25 per share. Viking Therapeutics pays -- of its earnings as a dividend. Amgen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VKTX or AMGN?

    Viking Therapeutics quarterly revenues are --, which are smaller than Amgen quarterly revenues of $9.1B. Viking Therapeutics's net income of -$35.4M is lower than Amgen's net income of $627M. Notably, Viking Therapeutics's price-to-earnings ratio is -- while Amgen's PE ratio is 39.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics is -- versus 4.80x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VKTX
    Viking Therapeutics
    -- -- -- -$35.4M
    AMGN
    Amgen
    4.80x 39.29x $9.1B $627M
  • Which has Higher Returns VKTX or LLY?

    Eli Lilly and has a net margin of -- compared to Viking Therapeutics's net margin of 32.59%. Viking Therapeutics's return on equity of -- beat Eli Lilly and's return on equity of 66.4%.

    Company Gross Margin Earnings Per Share Invested Capital
    VKTX
    Viking Therapeutics
    -- -$0.32 --
    LLY
    Eli Lilly and
    82.24% $4.88 $45.4B
  • What do Analysts Say About VKTX or LLY?

    Viking Therapeutics has a consensus price target of $99.13, signalling upside risk potential of 230.86%. On the other hand Eli Lilly and has an analysts' consensus of $979.86 which suggests that it could grow by 13.28%. Given that Viking Therapeutics has higher upside potential than Eli Lilly and, analysts believe Viking Therapeutics is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    VKTX
    Viking Therapeutics
    9 1 0
    LLY
    Eli Lilly and
    15 6 0
  • Is VKTX or LLY More Risky?

    Viking Therapeutics has a beta of 0.900, which suggesting that the stock is 10.034% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.416, suggesting its less volatile than the S&P 500 by 58.369%.

  • Which is a Better Dividend Stock VKTX or LLY?

    Viking Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.6% to investors and pays a quarterly dividend of $1.30 per share. Viking Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VKTX or LLY?

    Viking Therapeutics quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Viking Therapeutics's net income of -$35.4M is lower than Eli Lilly and's net income of $4.4B. Notably, Viking Therapeutics's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 73.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics is -- versus 17.36x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VKTX
    Viking Therapeutics
    -- -- -- -$35.4M
    LLY
    Eli Lilly and
    17.36x 73.87x $13.5B $4.4B
  • Which has Higher Returns VKTX or MRK?

    Merck & has a net margin of -- compared to Viking Therapeutics's net margin of 23.96%. Viking Therapeutics's return on equity of -- beat Merck &'s return on equity of 29.26%.

    Company Gross Margin Earnings Per Share Invested Capital
    VKTX
    Viking Therapeutics
    -- -$0.32 --
    MRK
    Merck &
    75.5% $1.48 $82.7B
  • What do Analysts Say About VKTX or MRK?

    Viking Therapeutics has a consensus price target of $99.13, signalling upside risk potential of 230.86%. On the other hand Merck & has an analysts' consensus of $116.67 which suggests that it could grow by 34.82%. Given that Viking Therapeutics has higher upside potential than Merck &, analysts believe Viking Therapeutics is more attractive than Merck &.

    Company Buy Ratings Hold Ratings Sell Ratings
    VKTX
    Viking Therapeutics
    9 1 0
    MRK
    Merck &
    13 9 0
  • Is VKTX or MRK More Risky?

    Viking Therapeutics has a beta of 0.900, which suggesting that the stock is 10.034% less volatile than S&P 500. In comparison Merck & has a beta of 0.383, suggesting its less volatile than the S&P 500 by 61.682%.

  • Which is a Better Dividend Stock VKTX or MRK?

    Viking Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.61% to investors and pays a quarterly dividend of $0.81 per share. Viking Therapeutics pays -- of its earnings as a dividend. Merck & pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VKTX or MRK?

    Viking Therapeutics quarterly revenues are --, which are smaller than Merck & quarterly revenues of $15.6B. Viking Therapeutics's net income of -$35.4M is lower than Merck &'s net income of $3.7B. Notably, Viking Therapeutics's price-to-earnings ratio is -- while Merck &'s PE ratio is 12.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics is -- versus 3.43x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VKTX
    Viking Therapeutics
    -- -- -- -$35.4M
    MRK
    Merck &
    3.43x 12.86x $15.6B $3.7B
  • Which has Higher Returns VKTX or PFE?

    Pfizer has a net margin of -- compared to Viking Therapeutics's net margin of 2.31%. Viking Therapeutics's return on equity of -- beat Pfizer's return on equity of 4.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    VKTX
    Viking Therapeutics
    -- -$0.32 --
    PFE
    Pfizer
    66.73% $0.07 $159.2B
  • What do Analysts Say About VKTX or PFE?

    Viking Therapeutics has a consensus price target of $99.13, signalling upside risk potential of 230.86%. On the other hand Pfizer has an analysts' consensus of $31.18 which suggests that it could grow by 22.11%. Given that Viking Therapeutics has higher upside potential than Pfizer, analysts believe Viking Therapeutics is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    VKTX
    Viking Therapeutics
    9 1 0
    PFE
    Pfizer
    7 13 1
  • Is VKTX or PFE More Risky?

    Viking Therapeutics has a beta of 0.900, which suggesting that the stock is 10.034% less volatile than S&P 500. In comparison Pfizer has a beta of 0.642, suggesting its less volatile than the S&P 500 by 35.808%.

  • Which is a Better Dividend Stock VKTX or PFE?

    Viking Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.62% to investors and pays a quarterly dividend of $0.43 per share. Viking Therapeutics pays -- of its earnings as a dividend. Pfizer pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VKTX or PFE?

    Viking Therapeutics quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.8B. Viking Therapeutics's net income of -$35.4M is lower than Pfizer's net income of $410M. Notably, Viking Therapeutics's price-to-earnings ratio is -- while Pfizer's PE ratio is 18.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics is -- versus 2.29x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VKTX
    Viking Therapeutics
    -- -- -- -$35.4M
    PFE
    Pfizer
    2.29x 18.11x $17.8B $410M
  • Which has Higher Returns VKTX or VRTX?

    Vertex Pharmaceuticals has a net margin of -- compared to Viking Therapeutics's net margin of 31.35%. Viking Therapeutics's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -3.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    VKTX
    Viking Therapeutics
    -- -$0.32 --
    VRTX
    Vertex Pharmaceuticals
    85.46% $3.50 $16.4B
  • What do Analysts Say About VKTX or VRTX?

    Viking Therapeutics has a consensus price target of $99.13, signalling upside risk potential of 230.86%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $498.34 which suggests that it could grow by 9.36%. Given that Viking Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Viking Therapeutics is more attractive than Vertex Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    VKTX
    Viking Therapeutics
    9 1 0
    VRTX
    Vertex Pharmaceuticals
    16 12 1
  • Is VKTX or VRTX More Risky?

    Viking Therapeutics has a beta of 0.900, which suggesting that the stock is 10.034% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.713%.

  • Which is a Better Dividend Stock VKTX or VRTX?

    Viking Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viking Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VKTX or VRTX?

    Viking Therapeutics quarterly revenues are --, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Viking Therapeutics's net income of -$35.4M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Viking Therapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics is -- versus 10.75x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VKTX
    Viking Therapeutics
    -- -- -- -$35.4M
    VRTX
    Vertex Pharmaceuticals
    10.75x 26.10x $2.9B $913M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Will Palantir Stock Be Worth in 2030?
What Will Palantir Stock Be Worth in 2030?

Palantir Technologies (NYSE: PLTR) has emerged from a growth slowdown…

Is Rollins Stock a Buy, Sell or Hold?
Is Rollins Stock a Buy, Sell or Hold?

Pest control giant Rollins (NYSE:ROL) is the parent company of…

Why Did Bill Ackman Buy Uber?
Why Did Bill Ackman Buy Uber?

In early 2025, billionaire investor Bill Ackman, CEO of Pershing…

Stock Ideas

Buy
59
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 111x

Sell
43
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
65
ATEX alert for Feb 12

Anterix [ATEX] is down 0.72% over the past day.

Buy
87
GDS alert for Feb 12

GDS Holdings [GDS] is up 0.32% over the past day.

Sell
30
SPSC alert for Feb 12

SPS Commerce [SPSC] is up 0.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock